IDH1 and neoplasm: Temozolomide, used frequently in the adult setting for its favorable toxicity profile, has a clear risk of hypermutation whilst IDH inhibitors have not been tested in the pediatric CNS tumor population and need further study to determine impact on tumor biology and efficacy at recurrence.